In the global pharmaceutical trade landscape, behind every order lies not just a simple delivery of goods, but also a journey of trust that transcends geographical, linguistic and regulatory barriers. Today, we are sharing the story of a Belgian customer's repeat purchase of retatrutide. This time, there was no lengthy inquiry and negotiation, nor repeated confirmation of terms - only a concise order and the simple instruction "Arrange as before."
The customer's decision to continue the order after our initial communication is the strongest affirmation of our process and service. It is like a stone dropped into a lake, seemingly light, yet within our service philosophy of "professional protection and complete trust", it creates a lasting and profound reverberation - making us even more convinced that only by solidly accumulating every entrusted matter can trust take root and grow over vast distances.
Ordering process
Mechanism of Action: Tri-Targeted Synergistic Regulation of Metabolic Balance
Retatrutide (development code name LY-3437943) is the world's first triple agonist that simultaneously activates the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). Its core mechanism of action is achieved through the following three pathways:
GLP-1R pathway
Inhibits appetite, delays gastric emptying, and reduces calorie intake;
Promotes insulin secretion, inhibits glucagon secretion, and directly lowers blood sugar levels.
GIPR pathway
Enhances insulin sensitivity, optimizes lipid distribution, and reduces liver fat accumulation;
Collaborates with GLP-1R to further suppress appetite, forming a "double satiety signal".
GCGR pathway
Promotes liver energy consumption and fat oxidation, increases heat production, and raises basal metabolic rate;
Reduces liver gluconeogenesis and lowers fasting blood sugar.
Complementarity of the triple pathways:
24-hour continuous metabolic regulation: GLP-1R and GIPR mainly act on post-meal metabolism, while GCGR dominates energy consumption during fasting, resulting in a simultaneous decrease in blood sugar, blood lipids, and liver lipids throughout the day.
Fat tissue preferential breakdown: Clinical data shows that approximately 83% of the weight lost by Retatrutide is fat tissue, effectively retaining lean body mass (muscle) and avoiding the metabolic rate decline caused by traditional weight loss.
Clinical efficacy: A double breakthrough in weight loss and metabolic improvement
Weight loss effect sets a new record
II-phase trial: During the 48-week treatment, the 12mg dose group had an average weight loss of 24.2% (about 27 kilograms), significantly better than the placebo group (2.1%) and existing therapies (such as semaglutide 16%, tilotropine 20%).
III-phase TRIUMPH-4 trial: During the 68-week treatment, the 12mg dose group had an average weight loss of 28.7% (about 32 kilograms), and the 9mg dose group had a weight loss of 26.4% (about 29 kilograms), surpassing all approved weight loss drugs.
Fat reduction ratio: MRI scans show that the visceral fat area of patients decreased by 69.8%, subcutaneous fat decreased by 54.8%, and the average waist circumference decreased by 18.4 centimeters.
Metabolic indicators improved comprehensively
Blood sugar control: The glycated hemoglobin (HbA1c) level of patients with type 2 diabetes decreased by 2.4%, and some patients approached the normal range (<5.7%).
Blood lipid optimization: Non-high-density lipoprotein cholesterol decreased by 26%, triglycerides decreased by 55%, and low-density lipoprotein cholesterol (LDL-C) decreased by 15%.
Cardiovascular risk reduction: High-sensitivity C-reactive protein (hsCRP) decreased by 40%, systolic blood pressure decreased by 14 mmHg, and reduced the risk of atherosclerosis.
Significant relief of obesity-related complications
Knee osteoarthritis: Pain score decreased by 76%, over 12% of patients had complete disappearance of pain, and knee joint function improved by 50%.
Metabolic-related fatty liver disease (MASLD): After 48 weeks of treatment, liver fat content decreased by 80%, and liver enzyme (ALT, AST) levels decreased by 60%.
Obstructive sleep apnea (OSA): Preliminary data show that the apnea-hypopnea index (AHI) improved by 30%.
Potential anti-cancer effect
Preclinical studies show that Retatrutide, by improving obesity-related metabolic disorders (such as insulin resistance, chronic inflammation), may inhibit the tumor microenvironment. In the triple-negative breast cancer model, the drug showed a 40% inhibition of tumor growth and enhanced chemotherapy efficacy.
Safety and Side Effect Management
Common Adverse Reactions
Gastrointestinal reactions: nausea (60%-70%), vomiting (30%-40%), diarrhea (20%-30%), constipation (10%-15%). These symptoms usually occur in the early stage of treatment and gradually subside over time.
Metabolic effects: A small number of patients may experience hypoglycemia (especially when combined with insulin therapy).
Serious Adverse Reactions (rare but require vigilance)
Pancreatitis: characterized by persistent abdominal pain, nausea/vomiting, jaundice, requiring immediate discontinuation of the medication and medical attention;
Cholecystic diseases: such as gallstones or cholecystitis, symptoms include right upper abdominal pain and fever;
Risk of medullary thyroid carcinoma (MTC): although animal experiments did not show a risk, GLP-1 class drugs need to monitor thyroid nodules.
Side Effect Management Strategies
Diet adjustment: Avoid high-fat and high-sugar foods during treatment, eat small meals more frequently;
Drug intervention: Severe nausea can be treated with antiemetic drugs (such as ondansetron) for a short period;
Dose adjustment: If side effects persist, the dose can be temporarily suspended or the target dose can be reduced.
Market Prospects: Reshaping the Obesity Treatment Landscape
Sales Forecast and Competitive Landscape
According to Evaluate, the sales of Retatrutide will reach 5 billion US dollars by 2030, making it another blockbuster product for Eli Lilly after Trelasopide.
Main Competitors Include:
Tirzepatide (Tirzepatide): GLP-1/GIP dual target, with sales of 5.3 billion US dollars in 2023, but its weight loss effect is slightly inferior to Retatrutide.
Orforglipron: Oral GLP-1R agonist, with a weight loss effect of 12%-14%, but requires daily administration.
MariTide: A peptide-conjugated drug developed by Amgen, administered once a month, with a weight loss of 14.5%, but has a higher risk of rebound after discontinuation.
Research Progress and Regulatory Dynamics
Retatrutide has initiated 8 Phase III trials, covering obesity, type 2 diabetes, knee osteoarthritis, MASLD, etc.
It is expected to complete the main trials in 2026 and submit for FDA approval in 2027. If approved, it will become the first triple-target weight loss drug.
The Double-Edged Sword of Transformative Drugs
Retatrutide 10mg demonstrates the potential of "one drug for multiple effects" in weight loss, metabolic improvement, and complication relief through its triple-target mechanism. It may redefine the standard of obesity treatment. However, its side effects (especially gastrointestinal reactions and sensory disorders at high doses) and long-term safety still need to be further verified. For patients, Retatrutide may be a "last-mile" weight loss solution, but they need to weigh the pros and cons under the guidance of doctors and combine lifestyle interventions for sustainable health management. In the future, with the release of Phase III data and the expansion of indications, Retatrutide is expected to become a landmark drug in the field of metabolic diseases.
